Cipla is targeting growth through a mix of inorganic expansion coupled with a spree of product launches in the ongoing financial year. The pharma major is targeting 2-3 peptide asset launches in the FY26.
The company recently released its yearly report for FY25, which highlights the key milestones achieved by the company in the year. From posting a 7 percent YoY increase in revenue to capacity expansion and pipeline development, here are the 5 highlights from Cipla’s annual report.
Cipla: North America expansion
North America is the biggest foreign market for Cipla, as 29 percent of its revenue comes from the region. While the company posted a moderate revenue growth of 3 percent in the region, it still managed to generate its all-time high revenue of $934 million in FY25 from the region.
While the region is dominated by companies like Johnson and Johnson, Pfizer, and Eli Lilly, the home market of some of the biggest pharmaceutical companies of the world, Cipla said that it has 1.66 percent of the market share in the United States generic market.
Cipla said that its Respiratory portfolio is doing well in the North American market Albuterol increasing its market share from 13 to 16 percent. Furthermore, Cipla filed 6 Respiratory assets, including gSymbicort and gQvar, while in the peptides and complex generics, the company filed 9 assets in FY25. Cipla is targeting to launch 2-3 peptide assets in the FY26.
Financial growth
Cipla posted Rs 27,548 crore in FY25 against the revenue of Rs 25,774 crore in FY24. Additionally, the company achieved its highest ever profit in the financial year, amounting to Rs 5273 crore. While the company’s PAT grew by 28 percent on YoY, its PAT margins also increased from 16 to 19 percent.
Furthermore, Cipla posted its highest ever Ebitda in the Financial Year 2025. The company’s Ebitda stood at Rs 7128 crore in FY25, while in the previous year, its Ebitda was Rs 6291 crore. Furthermore, Cipla announced a dividend of Rs 16 per equity share. Last year, the company paid a dividend of Rs 13 per equity share. The company said that it paid a special dividend of Rs 3 in celebration of its 90th anniversary. In total, Cipla paid Rs 1050 crore dividends to its investors.
Domestic market growth
Cipla’s domestic business grew by 7 percent in FY25. The company crossed the Rs 11000 crore revenue mark for its domestic business. 42 percent of Cipla’s revenue comes from its domestic operations. The company says that, by volume, it is the largest pharmaceutical company in India.
In the annual report, Cipla said that the company has 26 brands that generate revenue of over Rs 100 crore in a year. Additionally, the company said that 6 of its brands in the wellness category rank among 1st or second position in the country.
Capacity expansion
In FY25, Cipla has taken significant steps to expand its manufacturing capabilities across its manufacturing facilities across India and North America. At present, Cipla has the capacity to produce 32.15 billion units of tablets and capsules, 679 million units of respules, 48.3 million units of oral liquid, and many other pharmaceutical products.
In the United States, Cipla has invested in the Long Island and Fall River manufacturing facilities to increase the production of respiratory pharmaceuticals. While in India, Cipla has increased the production capacity of its Goa, Indore, Patalganga, and Bommasandra facilities. Each of these facilities will increase the production capacity from 2.6 million units to 39 million units.
Intellectual property and patent expansion
Cipla reported that it has a total of 79 registered patents globally. In FY25, the company was granted 22 patents and applied for 20 new patents. Furthermore, the annual report shows that Cipla launched 133 products globally in FY25.
Cipla is the third-largest pharmaceutical company in India by market capitalization. The company has a market cap of Rs 1.22 trillion. The 90-year-old company has a presence in over 80 countries worldwide.